Difference between revisions of "Bavituximab (PGN-401)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
|||
| Line 4: | Line 4: | ||
=Preliminary data= | =Preliminary data= | ||
==[[Non-small cell lung cancer]]== | ==[[Non-small cell lung cancer]]== | ||
| − | # Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Aug 24. [ | + | # Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. [http://www.lungcancerjournal.info/article/S0169-5002(14)00355-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25236982 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
Revision as of 15:26, 8 October 2017
Mechanism of action
Binds to phosphatidylserine, provoking an immune response.
Preliminary data
Non-small cell lung cancer
- Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. link to original article PubMed